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Resource utilization included surgical procedures, implants,
spectacles, visits to ophthalmologists and eye-centers, trans-
portation, and time lost by patients. Discount rates and sensi-
tivity analyses were performed. Two perspectives were
considered: Sickness Fund (SF) and Societal. RESULTS: Specta-
cle-free rates were >80% for ReSTOR® and 40% for MFIOLs.
Mean lifetime numbers of spectacles purchased were 4.2 with
ReSTOR®, 12.7 with MFIOLs, and 21.3 without PS. Early PS
avoided 0.80 late cataract surgeries per subjects. Surgical proce-
dure costs were €3292 for ReSTOR® and €2292 for other
MFIOLs, respectively. From the societal perspective, total undis-
counted costs for ReSTOR® were €5268, €7170 for other
MFIOLs, and €8492 without PS. With a 3% discount rate, these
costs were €4569, €5071 and €4244, respectively. From the SF
perspective, total undiscounted costs were €146 with ReSTOR®,
€437 with MFIOLs, and €1.688 without PS. With a 3% discount
rate, these costs were €76, €227 and €747, respectively. 
CONCLUSION: PS should decrease the undiscounted costs 
of vision care from both perspectives. For SF it is highly beneﬁ-
cial while PS remains unlisted for reimbursement. For Society,
the discounted incremental cost of avoiding spectacles at age 45
was less than €9/year. ReSTOR® improves patients’ lifestyle and
is a cost-effective alternative versus spectacles in presbyopic
patients.
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OBJECTIVE: To compare the lifetime costs and consequences of
liberating patients from spectacles, after cataract surgery, by
implanting the multifocal IOL “ReSTOR®” versus monofocal
IOLs. METHODS: A Markov model was created to follow
patient cohorts from cataract surgery until death. Prevalence
rates of patients not needing spectacles after cataract surgery
were obtained from a clinical trial. Resource utilization included
implant surgery, IOLs, spectacles, visits to ophthalmologists and
eye centers, transportation, and time lost by patients. Economic
perspectives were those of Society and Sick Funds (SF). Mortal-
ity rates were introduced into the model. Discount rates were
applied. Sensitivity analyses were performed. Patients were fol-
lowed from age 70 to 100 years. RESULTS: More than 80% of
patients implanted with ReSTOR® were spectacle-free com-
pared to about 10% with monofocal IOLs. The mean number
of spectacles purchased was 1.7 after ReSTOR® and 7.6 after
monofocal IOLs. Surgical costs were €3292 for ReSTOR® and
€2292 for monofocal IOLs. From the societal perspective, total
undiscounted cost estimates were €4384 with ReSTOR® com-
pared to €5359 with monofocal IOLs. With a 3% discount rate
these costs became €4226 and €4654, respectively. From the SF
perspective, total undiscounted cost estimates were €2350 with
ReSTOR® and €2553 with monofocal IOLs. With a 3% dis-
count these costs became €2334 and €2481, respectively. Costs
and intervals between spectacle replacements were the most sen-
sitive parameters. CONCLUSION: From both the societal and
SF perspectives, undiscounted savings achieved by liberating
patients from spectacles counterbalanced the initially higher cost
of ReSTOR®. For Society, the discounted incremental cost of
avoiding spectacles after ReSTOR® implants was less than
€13/year, and SF saved money. ReSTOR® improves patients’
lifestyle and is a cost-effective alternative versus spectacles in
patients requiring cataract surgery.
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BACKGROUND: European studies have identiﬁed primary
open angle glaucoma (POAG) as the second leading cause of
blindness, accounting for 8–10% of blindness in older people.
The objective of this study was to estimate the societal costs and
the quality of life among patients with late stage POAG.
METHODS: Charts of late stage POAG patients in France,
Germany, the UK and Denmark were reviewed and the patients
were interviewed. Costs and utility values of health related
quality of life were estimated (based on resource use multiplied
with unit costs and on EQ-5D questionnaire). RESULTS: 162
patients were included. Average level of visual acuity was 0.28
and 0.11 of the best and worst eye, respectively. Annual health
maintenance costs of late stage glaucoma patients are €830 (SD:
€445). This does not include costs of surgery and larger proce-
dures. Purchase costs of devices amount to €2045 per patient.
Most importantly, however, are costs of home care, which
average €2703 per year. With respect to the health related quality
of life the average score is 0.67 and best predictor of QoL is
visual acuity of the patients’ best eye (negatively correlated, p =
0.005). Best eye visual acuity is also negatively correlated with
health care maintenance costs (p = 0.024). With respect to home
care costs the correlation is positive but not signiﬁcant. CON-
CLUSIONS: This study shows that late stage glaucoma is asso-
ciated with considerable health care and—in particular—social
care costs (home care). It is an important ﬁnding that mainte-
nance health care costs is negatively correlated with visual acuity
(and thereby QoL). A lower visual acuity is predictive of lower
QoL.
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OBJECTIVE: To assess the cost-effectiveness of bimatoprost,
latanoprost, and travoprost monotherapy in patients with open-
angle glaucoma in Denmark, Norway, and Sweden (Scandi-
navia). METHODS: Cost-effectiveness analysis was performed
using a Markov decision-analytic health economic model with
stable and progressed glaucoma as the health states. Transition
probabilities for primary open-angle and exfoliation glaucoma
were derived from published medical literature, and information
regarding clinical practice patterns was obtained from surveys
completed by 45 ophthalmologists dispersed throughout each of
the countries. Country-speciﬁc unit costs were used for medica-
tions, clinic visits, diagnostics, and outpatient services. Quality
of life weights for various levels of visual acuity ranged from 0.50
to 0.68, and the effectiveness metric was the quality-adjusted life
year (QALY). A 5-year time horizon was adopted, analyses were
from a payer perspective, and costs were discounted at 3% per
year. RESULTS: Effectiveness (years till progression) was within
a narrow range (3.2048 to 3.2613 QALYs) across all products
